Resource Summary Report

Generated by dkNET on Sep 3, 2026

MDA-MB-435S

RRID:CVCL_0622
Type: Cell Line

Proper Citation

RRID:CVCL_0622

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0622

Proper Citation: RRID:CVCL_0622

Description: Cell line MDA-MB-435S is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: PMID:2007622, PMID:10700188, PMID:12354931, PMID:12661003, PMID:15677628, PMID:16397213, PMID:16541312, PMID:19593635, PMID:20070913, PMID:22460905, PMID:23601657, PMID:26589293, PMID:28940260, PMID:30894373, PMID:31068700

Comments: Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-435S

Synonyms: MDA-MB-435s, MDA-MB-435 S, MDA-MB-435-S, MDAMB435S, BrCL15

Cross References: BTO:BTO_0003941, CLO:CLO_0007638, CLDB:cl7142, ArrayExpress:E-MTAB-2770, ATCC:HTB-129, BCRJ:0165, BioGRID_ORCS_Cell_line:567, BioSample:SAMN10987989, cancercelllines:CVCL_0622, CCRID:1101HUM-PUMC000015, CCRID:3101HUMTCHu36, CCTCC:GDC0053, Cell_Model_Passport:SIDM01222, ChEMBL-Cells:CHEMBL4483174, ChEMBL-

Targets:CHEMBL4483284, CLS:300277, Cosmic:809237, Cosmic:871155, Cosmic:894089, Cosmic:904381, Cosmic:1044202, Cosmic:1046951, Cosmic:1287922, Cosmic:1289399, Cosmic:1523969, Cosmic:1609477, Cosmic:2301531, DepMap:ACH-000884, GEO:GSM149983, GEO:GSM149991, GEO:GSM149999, GEO:GSM421877, GEO:GSM887298, GEO:GSM888373, GEO:GSM1374657, ICLC:HTL03006, KCB:KCB 200773YJ, LiGeA:CCLE_408, LINCS_HMS:50030, LINCS_LDP:LCL-1307, PRIDE:PXD016837, Progenetix:CVCL_0622, PubChem_Cell_line:CVCL_0622, Wikidata:Q54904637

ID: CVCL_0622

Hierarchy: cvcl_0417

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260904T014624+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-435S.

Warning: Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565.
Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.. Warning: Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565.
Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative..

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Chen Y, et al. (2026) Ceritinib induces ferroptosis via TRIM21-mediated GLUT1 ubiquitination and AMPK-driven metabolic reprogramming in breast cancer. iScience, 29(6), 115846.

Blackman SA, et al. (2026) Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. The Journal of biological chemistry, 302(6), 111476.

Rasbach E, et al. (2025) Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. Molecular cancer, 24(1), 310.

Shin S, et al. (2025) mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport. Molecular cell, 85(18), 3486.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Dilasser F, et al. (2025) A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer. Cell reports. Medicine, 6(7), 102233.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. Cancer discovery, 14(12), 2450.

Sandor LF, et al. (2024) De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis. Cell reports, 43(3), 113936.

Zhang W, et al. (2023) AEP-cleaved DDX3X induces alternative RNA splicing events to mediate cancer cell adaptation in harsh microenvironments. The Journal of clinical investigation, 134(3).

Li H, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer cell, 40(1), 36.

Matas-Rico E, et al. (2021) Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells. Cell reports, 37(7), 110013.

Yoon SO, et al. (2017) Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Molecular cell, 67(3), 512.

Pal D, et al. (2017) TGF-? reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. eLife, 6.